Chugai Pharmaceutical Co., Ltd.
4519
株式のランク
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
株価
$41.60
時価総額
$68.46B
変化（1日）
0.94%
変化（1年）
-12.56%
国
JP
取引 Chugai Pharmaceutical Co., Ltd. (4519)
カテゴリー
Healthcare
Chugai Pharmaceutical Co., Ltd.（4519）のP/E比率
October 2026 時点のP/E比率 TTM 23.09
Chugai Pharmaceutical Co., Ltd. の最新の財務報告および株価によると、現在の P/E (TTM) は 23.09 です。2024 年末時点での P/E は 29.74 でした。
Chugai Pharmaceutical Co., Ltd. の P/E 比率の履歴（2003 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 23.09 | -26.13% |
| 2025 | 31.26 | 5.11% |
| 2024 | 29.74 | 10.13% |
| 2023 | 27.00 | 82.51% |
| 2022 | 14.80 | -27.00% |
| 2021 | 20.27 | -51.88% |
| 2020 | 42.12 | 20.27% |
| 2019 | 35.02 | -7.26% |
| 2018 | 37.76 | -12.94% |
| 2017 | 43.37 | 26.84% |
| 2016 | 34.19 | -9.68% |
| 2015 | 37.86 | 19.46% |
| 2014 | 31.69 | 27.40% |
| 2013 | 24.88 | 33.46% |
| 2012 | 18.64 | -4.90% |
| 2011 | 19.60 | 0.15% |
| 2010 | 19.57 | 16.98% |
| 2009 | 16.73 | -30.02% |
| 2008 | 23.91 | 9.42% |
| 2007 | 21.85 | -38.80% |
| 2006 | 35.70 | 35.47% |
| 2005 | 26.35 | -4.37% |
| 2004 | 27.56 | -7.62% |
| 2003 | 29.83 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 40.53 | 75.52% |
US
|
|
| 38.50 | 66.71% |
US
|
|
| 79.88 | 245.92% |
US
|
|
| 116.96 | 406.50% |
US
|
|
| 22.25 | -3.65% |
CH
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。